These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34134903)

  • 1. Conversational Vocal Intensity in Parkinson's Disease: Treatment and Environmental Comparisons.
    Konnai R; Van Harn M; Silbergleit A
    J Voice; 2023 Sep; 37(5):707-715. PubMed ID: 34134903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of an extended version of the lee silverman voice treatment on voice and speech in Parkinson's disease.
    Spielman J; Ramig LO; Mahler L; Halpern A; Gavin WJ
    Am J Speech Lang Pathol; 2007 May; 16(2):95-107. PubMed ID: 17456888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.
    Sackley CM; Rick C; Au P; Brady MC; Beaton G; Burton C; Caulfield M; Dickson S; Dowling F; Hughes M; Ives N; Jowett S; Masterson-Algar P; Nicoll A; Patel S; Smith CH; Woolley R; Clarke CE;
    Trials; 2020 May; 21(1):436. PubMed ID: 32460885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive voice treatment (LSVT®LOUD) for Parkinson's disease following deep brain stimulation of the subthalamic nucleus.
    Spielman J; Mahler L; Halpern A; Gilley P; Klepitskaya O; Ramig L
    J Commun Disord; 2011; 44(6):688-700. PubMed ID: 21724193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Intensive Voice Treatment (The Lee Silverman Voice Treatment [LSVT LOUD]) in Subjects With Multiple Sclerosis: A Pilot Study.
    Baldanzi C; Crispiatico V; Foresti S; Groppo E; Rovaris M; Cattaneo D; Vitali C
    J Voice; 2022 Jul; 36(4):585.e1-585.e13. PubMed ID: 32819780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis.
    Narayana S; Fox PT; Zhang W; Franklin C; Robin DA; Vogel D; Ramig LO
    Hum Brain Mapp; 2010 Feb; 31(2):222-36. PubMed ID: 19639554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lee Silverman Voice Treatment for people with Parkinson's: audit of outcomes in a routine clinic.
    Wight S; Miller N
    Int J Lang Commun Disord; 2015; 50(2):215-25. PubMed ID: 25469736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of Lee Silverman Voice Treatment on daily voice use in Parkinson's disease as measured with a portable voice accumulator.
    Körner Gustafsson J; Södersten M; Ternström S; Schalling E
    Logoped Phoniatr Vocol; 2019 Oct; 44(3):124-133. PubMed ID: 29447488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Lee Silverman Voice Treatment (LSVT LOUD®) on swallowing and cough in Parkinson's disease: A pilot study.
    Miles A; Jardine M; Johnston F; de Lisle M; Friary P; Allen J
    J Neurol Sci; 2017 Dec; 383():180-187. PubMed ID: 29246611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of Lee Silverman Voice Treatment (LSVT LOUD®) on voice, communication, and participation: Findings from a prospective, longitudinal study.
    Bryans LA; Palmer AD; Anderson S; Schindler J; Graville DJ
    J Commun Disord; 2021; 89():106031. PubMed ID: 33259945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perception of Physical Demand, Mental Demand, and Performance: A Comparison of Two Voice Interventions for Parkinson's Disease.
    Richardson K; Huber JE; Kiefer B; Snyder S
    Am J Speech Lang Pathol; 2022 Sep; 31(5):1963-1978. PubMed ID: 35858264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of PD Check-In, a model for supported self-managed maintenance of speech in Parkinson's disease: A Phase 1 study.
    Finnimore A; Theodoros D; Rumbach AF
    Int J Lang Commun Disord; 2023 Mar; 58(2):241-255. PubMed ID: 36036751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study.
    El Sharkawi A; Ramig L; Logemann JA; Pauloski BR; Rademaker AW; Smith CH; Pawlas A; Baum S; Werner C
    J Neurol Neurosurg Psychiatry; 2002 Jan; 72(1):31-6. PubMed ID: 11784821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Acceptance of a Lombard-response Device for Hypophonia in Parkinson's Disease.
    Adams S; Kumar N; Rizek P; Hong A; Zhang J; Senthinathan A; Mancinelli C; Knowles T; Jog M
    Can J Neurol Sci; 2020 Sep; 47(5):634-641. PubMed ID: 32389143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of voice rehabilitation in people with MS: A double-blinded long-term randomized controlled trial.
    Crispiatico V; Baldanzi C; Napoletano A; Tomasoni L; Tedeschi F; Groppo E; Rovaris M; Vitali C; Cattaneo D
    Mult Scler; 2022 Jun; 28(7):1081-1090. PubMed ID: 34652243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lee Silverman Voice Treatment for dysarthria in patients with Parkinson's disease: a systematic review and meta-analysis.
    Yuan F; Guo X; Wei X; Xie F; Zheng J; Huang Y; Huang Z; Chang Z; Li H; Guo Y; Chen J; Guo J; Tang B; Deng B; Wang Q
    Eur J Neurol; 2020 Oct; 27(10):1957-1970. PubMed ID: 32539227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Singing in groups for Parkinson's disease (SING-PD): a pilot study of group singing therapy for PD-related voice/speech disorders.
    Shih LC; Piel J; Warren A; Kraics L; Silver A; Vanderhorst V; Simon DK; Tarsy D
    Parkinsonism Relat Disord; 2012 Jun; 18(5):548-52. PubMed ID: 22436653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Speech treatment in Parkinson's disease: Randomized controlled trial (RCT).
    Ramig L; Halpern A; Spielman J; Fox C; Freeman K
    Mov Disord; 2018 Nov; 33(11):1777-1791. PubMed ID: 30264896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovative technology for the assisted delivery of intensive voice treatment (LSVT®LOUD) for Parkinson disease.
    Halpern AE; Ramig LO; Matos CE; Petska-Cable JA; Spielman JL; Pogoda JM; Gilley PM; Sapir S; Bennett JK; McFarland DH
    Am J Speech Lang Pathol; 2012 Nov; 21(4):354-67. PubMed ID: 23071195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidimensional voice assessment after Lee Silverman Voice Therapy (LSVT
    Marchese MR; Proietti I; Longobardi Y; Mari G; Ausili Cefaro C; D'Alatri L
    Acta Otorhinolaryngol Ital; 2022 Aug; 42(4):348-354. PubMed ID: 36254651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.